Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where did you get those numbers?
This is what I found from their last 10-Q and current OTC Markets report:
Period end dates July 31, 2011
(ii.) Shares of common stock authorized 2,900,000,000
(iii.) Number of shares of common stock outstanding 325,265,052
(iv.) Freely tradable shares of common stock (public float) 26,320,682*
Shares Outstanding 332,765,052 a/o Sep 19, 2011
Float 33,820,682 a/o Sep 19, 2011
Authorized Shares 3,000,000,000 a/o Sep 19, 201
They had an 8-k out that day about a change in debt note or something.
EMPM news
EMPM news
EMPM news
LOS ANGELES, CA, Sep 30, 2011 (MARKETWIRE via COMTEX) -- Empire Post Media, Inc.
(EMPM) announces that its wholly-owned subsidiary, Hybrid-Reality Entertainment,
has cast actress Mackenzie Phillips as the narrator of the company's "Journey
Beyond" television reality show pilot.
Daughter of John Phillips of The Mamas & The Papas, Ms. Phillips made her debut
as an actress in George Lucas's "American Graffiti" and went on to star for eight
seasons in the television series 'One Day at a Time." Over the years, she
appeared in numerous television and motion picture projects. Most recently, she
was featured in the 2010 season of "Celebrity Rehab with Dr. Drew." She is
currently shooting a project for Oprah Winfrey's OWN network.
"Journey Beyond" is a one-hour series that explores a broad range of psychic and
paranormal events, based on the real experiences of real people. The program is
being distributed globally by The Fremantle Corporation, a global distribution
company, with over 50 years of experience in international distribution and
co-production.
ABOUT EMPIRE POST MEDIA Empire Post Media is an entertainment company which
focuses on three key areas in the film and television industry: post-production
services, 2D to 3D production and conversion and the creation, development,
production and marketing of 2D and 3D television programming.
Further information about Empire Post Media, Fremantle Corporation, and Hybrid
reality Entertainment can be obtained from their websites.
http://www.empirepostmedia.comhttp://www.hybridrealityentertainment.com
http://www.fremantlecorp.com/
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Matters discussed in
this press release may constitute forward-looking statements. Forward-looking
statements include statements concerning plans, objectives, goals, strategies,
future events or performance, and underlying assumptions and other statements,
which are other than statements of historical facts.
The words "believe," "anticipate," "intend," "estimate," "forecast," "project,"
"plan," "potential," "will," "may," "should," "expect," "pending" and similar
expressions identify forward-looking statements.
The forward-looking statements in this press release are based upon various
assumptions, which are inherently subject to significant uncertainties and
contingencies which are difficult or impossible to predict and are beyond our
control, we cannot assure you that we will achieve or accomplish these
expectations, beliefs or projections.
Peter Dunn
President
Empire Post Media, Inc.
Tele: 310-472-5138
I wish I did, man. I wish I did, lol
EMPM chart looking good. At resistance here, .37
EMPM setting up. High accumulation. MACD crossing, watch out after .37!
EMPM setting up for a move higher. Needs to push through this .37 resistance and then watch out!
Looking Sweet! Like taking candy for a baby
Well I hope it hits $2 today! lol
Nice news. Need a break in this .30 resistance.
Thanks!
Who is this email from? Thanks
EMPM looking good today. In at .25. Oversold and MACD about to turn.
EMPM movement. MACD about to turn. Way oversold
EMPM breaking out on Volume this morning. Thin, Oversold, News.
In at .25
In EMPM @ .25
Thin, Way Oversold, News Out
In EMPM @ .25
Watching here from .0002
Now back to STXS :p
More and more insider buys rolling in
More insider buys
SYMBOL: STXS
FILER: ALAFI CHRISTOPHER D
TITLE: Director
DATE TRANSACTION SHARES PRICE VALUE
9/12/11 Purchase 64,468 $1.34 $86,387
OWNERSHIP: 228,286 (Direct) 4,149,598 (Indirect)
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8145036
Did you play it? If you did when I posted, you should be up a cool 35 - 40%
It's in a Form 4 required to be filed by the SEC. You can see it here: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8143073
You can see other financial documents here: http://www.otcmarkets.com/stock/STXS/financials
News
SYMBOL: STXS
FILER: ALAFI CHRISTOPHER D
TITLE: Director
DATE | SHARES | PRICE | VALUE
9/9/11 | 35,532 | $1.33 | $47,258
K. Good luck elswhere. May I suggest ANX
Check out YONG on the weekly chart. I think it has a strong chacne of turning here. Especially with the $7 mil stock buys from Morgan Stanley over the past month
the weekly, 2 year chart
From Webcast: Major product coming out in December
iBox/Stickies updated.
Webcast from yesterday's Stifel, Nicolaus & Company Inc. Healthcare Conference
Speaker - Mr. Michael Kaminski CEO
http://www.veracast.com/stifel/healthcare2011/main/player.cfm?eventName=1153_stereo
Results Featured at Europe's Largest Medical Meeting, European Society of
Cardiology
ST. LOUIS--(BUSINESS WIRE)--August 30, 2011--
Stereotaxis, Inc. (NASDAQ: STXS) announced today that the results of the
Study to Obliterate Persistent Ventricular Tachycardia (STOP-VT) was presented
at the European Society of Cardiology (ESC) 2011 Congress held in Paris, France
on Sunday, August 28.
The STOP-VT study is the first-ever, prospective multicenter evaluation of
magnetic navigation for VT ablation. The trial, led by Assoc. Prof. Petr
Neuzil, MD, PhD, Head of Cardiology and Director of the Cardiac Arrhythmia
Service at the Na Homolce Hospital in Prague, Czech Republic was conducted at
four of the world's most prominent arrhythmia treatment centers, including,
Hospital of the University of Pennsylvania, Indiana University School of
Medicine, and Na Homolce Hospital, University of Leipzig. Fifty-three patients
with previous severe heart disease were treated with ventricular tachycardia
(VT) with the Stereotaxis Robotic Ablation System. The acute success rate in
the study was an impressive 94 percent, and no patients suffered a major
complication. The acute success results obtained from the STOP-VT study are
10-15 percent higher than similar published studies using conventional ablation
techniques.
"VT is one of the most challenging arrhythmia facing electrophysiologists due
to complex anatomy, the sensitive nature of ventricular tissue, and potentially
lethal outcomes," said Prof Neuzil. "Catheter ablation of VT, one of the
fastest growing EP procedures globally, requires the delivery of robust lesions
for clinical success. The main advantage of Stereotaxis for treatment of
ventricular tachycardia is the precise mapping and identification of the
critical diseased portions of the heart that allows physicians to perform
ablation in a more effective way. The results of the trial exceeded our
expectations, both in terms of acute outcomes as well as overall safety."
Prof Neuzil presented the STOP-VT data at ESC 2011 on Sunday, August 28. Due
to the significance of the study, Prof Neuzil also discussed the study at an
ESC press conference on Monday, August, 29, "Arrhythmias in the Real World."
"VT is a potentially lethal heart rhythm disorder that requires highly
precise mapping and effective lesion delivery for successful treatment," said
Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis. "The
significant placement of the STOP-VT study results at the world's largest
cardiology meeting reinforces the exceptional value that Stereotaxis brings to
this complex life-saving procedure."
About Stereotaxis www.stereotaxis.com www.odysseyexperience.com
Stereotaxis designs, manufactures and markets an advanced cardiology
instrument control system for use in a hospital's interventional surgical suite
to enhance the treatment of coronary artery disease and arrhythmias. The
Niobe(R) Remote Magnetic Navigation System is designed to enable physicians to
complete more complex interventional procedures by providing image guided
delivery of catheters and guidewires through the blood vessels and chambers of
the heart to treatment sites. This is achieved using computer-controlled,
externally applied magnetic fields that govern the motion of the working tip of
the catheter or guidewire, resulting in improved navigation, shorter procedure
time and reduced x-ray exposure.
Stereotaxis' Odyssey(TM) portfolio of products provides an innovative
enterprise solution for integrating, recording and networking interventional
lab information within hospitals and around the world. Odyssey(TM) Vision
integrates data for magnetic and standard interventional labs, enhancing the
physician workflow through a consolidated display of multiple systems and
eliminating the challenge of interacting simultaneously with many separate
diagnostic systems. Odyssey(TM) Enterprise Cinema then captures a complete
record of synchronized procedure data that can be viewed live or from a
comprehensive archive of cases performed. Odyssey(TM) then enables hospitals to
efficiently share live and recorded clinical data anywhere around the world to
maximize referrals and promote collaboration.
The core components of the Stereotaxis systems have received regulatory
clearance in the U.S., Europe, Canada and elsewhere. For more information,
please visit www.stereotaxis.com and www.odysseyexperience.com.
This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,"
"expect" or similar expressions. Forward-looking statements inherently involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, continued acceptance of the
Company's products in the marketplace, the effect of global economic conditions
on the ability and willingness of customers to purchase our systems and the
timing of such purchases, competitive factors, changes resulting from the
recently enacted healthcare reform in the U.S., including changes in government
reimbursement procedures, dependence upon third-party vendors, timing of
regulatory approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By making these
forward-looking statements, the Company undertakes no obligation to update
these statements for revisions or changes after the date of this release. There
can be no assurance that the Company will recognize revenue related to its
purchase orders and other commitments in any particular period or at all
because some of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In addition, these
orders and commitments may be revised, modified, delayed or canceled, either by
their express terms, as a result of negotiations, or by overall project changes
or delays.
CONTACT: Company Contact:
Stereotaxis, Inc.
Rod McCrimmon,
314-678-6100
Rod.McCrimmon@stereotaxis.com
or
Investor
Contact:
Stereotaxis, Inc.
Frank Cheng,
314-678-6100
Frank.Cheng@stereotaxis.com
or
Media Contact:
Schwartz
Communications
Krystin Hayward/Kirsten Fallon,
781-684-0770
Stereotaxis@schwartzcomm.com
SOURCE: Stereotaxis, Inc.
Copyright Business Wire 2011
(END) Dow Jones Newswires
08-30-11 1724ET
17:24 083011
SOURCE: Form 4
ISSUER: STEREOTAXIS INC
SYMBOL: STXS
FILER: KAMINSKI MICHAEL P
TITLE: Chief Executive Officer
DATE TRANSACTION SHARES PRICE VALUE
9/1/11 Purchase 10,400 $1.43 $14,872
OWNERSHIP: 125,567 (Direct) 3,700 (Indirect)
The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.
Insider Data Source: The Washington Service
(info@washingtonservice.com or 301-913-5100)
(END) Dow Jones Newswires
09-06-11 1209ET
12:09 090611
Holding up really well even with all the sells going through - http://ih.advfn.com/p.php?pid=trades&symbol=STXS
The slump might be over. 3.45 currently
Slow and steady wins the race!